EGT Timmmmmmberrrrrr

On the move....Suuuuuuweeeeee!!!! Oink Oink

EEE had a filing yesterday, don't think it means much but the pps is dropping today.

have some, looks like it setting up imo

I know alot here seem to hold a stock they really like. I don't know what your entry is but probably safe to say you were up quite a %. Always, always, always take some profits when your up big, I don't care how much you believe where a stock is headed eventually, there gonna go up and down before it gets there. 99% of the time you'll be glad you did. IMO

No offense but I've heard people saying that before and it hasn't seem to made a difference for the past year. You'll get them.

C'mon mods, leave my last post up for a bit!

IMO, JD didn't understand this land we call the "stinky pinkies", took some bad advice, slept w/ the devil, the stock got syphillis, and is now feeling the pain as are his shareholders for those mistakes. I don't think this was all intentional, it "just felt good" at the time. Just a case of not understanding the market and the money mongers that live here. Has he dug the hole deep, does he have what it takes to crawl his way out???? JMHO

Whoa whats going on here?? What year is it? Is this the ETIM or EXPH board?? lol. The people and the posting today brought me back a couple years.

EGT, lookin like a 1 hit wonder. Hope everyone didn't F up that trade as bad as I did.

EEE, 1.10 wall coming down

EEE, some volume trickling in. Looking for a pop soon

I was just f'n with you since it made a nice move already last week. Meant no harm.

Looks to me like you have week old info, lol

RBDC worth another shot on that news??

EEE setting up for a move soon, IMO

BCLE,Oh boy, I remember this bitch from about a year ago. Ole Pannetta scammed a bunch of people pumping this one. Total tank job from about .20 to zero in a few days I believe then the good ole RS. Major bagholders.

It is weird but it's been doing it for months. I never seen anything quite like it. Nice close today

yep, looking like it could go here.

KERX NEWS.

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming




Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST)

NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that four abstracts on KRX-0401 (Perifosine), the Company's Akt-inhibitor for cancer, were accepted for presentation during poster sessions taking place at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held in Orlando, Florida from May 29 to June 2.

All of the clinical data to be presented demonstrates the potential clinical efficacy of KRX-0401, both as a single agent and in combination with other approved agents, in the treatment of patients with advanced renal cell carcinoma, colorectal cancer and GIST.

Abstracts selected for presentation are as follows:

Renal Cell Carcinoma (RCC)

Friday, May 29th, 2009:


#5034: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

Lead Author: Nicholas Vogelzang, MD

Poster Discussion: 5:00pm-6:00pm (Level 2, West Hall F5)

Sunday, May 31st, 2009:


#5101: A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI).

Lead Author: Daniel Cho, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

Colorectal Cancer

Sunday, May 31st, 2009:


#4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

Lead Author: Sasha Vukelja, MD

Poster Session: 8:00am - 12:00pm (Level 2, West Hall C)

Gastrointestinal Stromal Tumor (GIST)

Sunday, May 31st, 2009:


#10563: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Lead Author: Anthony Conley, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)


Copies of these abstracts are currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in our website and in the American Society of Clinical Oncology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT: Lauren Fischer Director Investor Relations Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965 E-mail:

DATASOURCE: Keryx Biopharmaceuticals, Inc.


CONTACT: Lauren Fischer, Director, Investor Relations, Keryx

Biopharmaceuticals, Inc., +1-212-531-5965,


Web Site: http://www.keryx.com/

KERX NEWS

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming




Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST)

NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that four abstracts on KRX-0401 (Perifosine), the Company's Akt-inhibitor for cancer, were accepted for presentation during poster sessions taking place at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held in Orlando, Florida from May 29 to June 2.

All of the clinical data to be presented demonstrates the potential clinical efficacy of KRX-0401, both as a single agent and in combination with other approved agents, in the treatment of patients with advanced renal cell carcinoma, colorectal cancer and GIST.

Abstracts selected for presentation are as follows:

Renal Cell Carcinoma (RCC)

Friday, May 29th, 2009:


#5034: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

Lead Author: Nicholas Vogelzang, MD

Poster Discussion: 5:00pm-6:00pm (Level 2, West Hall F5)

Sunday, May 31st, 2009:


#5101: A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI).

Lead Author: Daniel Cho, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

Colorectal Cancer

Sunday, May 31st, 2009:


#4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

Lead Author: Sasha Vukelja, MD

Poster Session: 8:00am - 12:00pm (Level 2, West Hall C)

Gastrointestinal Stromal Tumor (GIST)

Sunday, May 31st, 2009:


#10563: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Lead Author: Anthony Conley, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)


Copies of these abstracts are currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in our website and in the American Society of Clinical Oncology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT: Lauren Fischer Director Investor Relations Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965 E-mail:

DATASOURCE: Keryx Biopharmaceuticals, Inc.


CONTACT: Lauren Fischer, Director, Investor Relations, Keryx

Biopharmaceuticals, Inc., +1-212-531-5965,


Web Site: http://www.keryx.com/

Party Bash/Memorial Day Contest picks

EEE & GMO

GMO, sorry, should have read the rules

EEE then if it's not too late.

Party Bash/Memorial Day Contest picks

TMR & KERX

Just based on the financials alone, IMO this has no where to go but up. Not to mention a very bullish looking chart. There cash on hand alone gives this a book value of .32. I'm honestly shocked this traded back down to the .30's. Looking to buy back what I flipped the other day.

EGT, What the hell is a bear bounce?

The trading leading up to the run did seem very "odd" to me. Very few retailers bought shares below this point IMO, so wheres all this selling coming from the past days at these levels??? Something definatly not right here???? I cut loose most of my shares for some decent bank but I left alot of dough on the table dammit.

TMR a buy at .30 you think?

Varok, whats your take on KERX now?

KERX, the big boys are still buying, check out OBV. Headed higher IMO

EEE 1.16 pre-market. I was so close to selling this yesterday. If i wouldn't have screwed up entering my order i would have been out. Wonder whats up?

EEE at support, ma100 about to cross the 200. Hope this holds here. If not, I think it goes to .80

EGT watch those stupid whackers chase now

KERX .46 turning back up. This ones headed much higher IMO

KERX, turning north. A major move up still in store for this one IMO

You listen to the CC? I won't have time till maybe tonight. Anything in there to create a concern. Sure thought this would be trading higher off the financials, still early though.

KERX, MA50 crossing MA100. This should head much higher IMO

KERX, this ones headed for a buck IMO

KERX positive earnings out! This is huge IMO. 141k traded after hours at a high of .55. Already seen .60's this morning. Headed back over a buck, IMO. 52 week high is .57

Link back for news!

KERX positive earnings, this is huge. Breaking 52 week high already in pre-market. Headed over a buck IMO.

Has a beautiful chart to go with it. This along w/ my EGT, I'm a pretty happy man this a.m.

KERX fyi, i've been swinging this for months and currently have an ave. of .23 so I'm in good shape. I really can't see any reason for this to turn back down, at least for the next quarter. Look at those ma's lining up on the chart, beautiful. I'll continue to swing it but fully expect this to rise above a dollar soon. 52 week high is only pennies away now from where it was trading after hours. Break above that could ignite it imo, gl